3.54  0.22 (6.63%)		04-22 12:59
Open: 3.34 High: 3.58 Volume: 358,847		Pre. Close: 3.32 Low: 3.32 Market Cap: 140(M)

Short term
Mid term
Targets	6-month :	4.18	1-year :	4.88
Resists	First :	3.57	Second :	4.18
Pivot price	0
Supports	First :	3.41	Second :	3.31
MAs	MA(5) :	0	MA(20) :	0
	MA(100) :	0	MA(250) :	0
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	0	D(3) :	0
RSI	RSI(14): 0
52-week	High :	3.57	Low :	3.31

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ THAR ] has closed Bollinger Bands are 0% narrower than normal.

If tomorrow:	Open lower	Open higher
High:	-	-
Low:	-	-
Close:	-	-

Tharimmune, Inc., a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1). It has a research collaboration and product license agreement with Minotaur Therapeutics, Inc. for the development of proprietary targeted biologics. The company was formerly known as Hillstream BioPharma, Inc. and changed its name to Tharimmune, Inc. in September 2023. Tharimmune, Inc. was incorporated in 2017 and is headquartered in Bridgewater, New Jersey.

Tue, 17 Feb 2026
Tharimmune rebrands to Canton Strategic Holdings with new NASDAQ ticker - Investing.com

Tue, 17 Feb 2026
Tharimmune, Inc. will Change its Ticker to CNTN from THAR - marketscreener.com

Tue, 17 Feb 2026
Tharimmune rebrands as Canton Strategic Holdings with new ticker CNTN - Investing.com

Mon, 02 Feb 2026
Ex-CFTC regulator joins Tharimmune board amid blockchain finance shift - Stock Titan

Fri, 30 Jan 2026
Tharimmune Shareholders Approve Directors, Warrant-Linked Share Issuances and 7M Share Plan Boost - Yahoo Finance

Thu, 29 Jan 2026
THAR Price Today: Tharimmune, Inc. Stock Price, Quote & Chart | MEXC - MEXC

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.